Medical Coverage Policy | Retinal Telescreening for Diabetic Retinopathy

EFFECTIVE DATE: 01|01|2021
POLICY LAST UPDATED: 10|14|2020

OVERVIEW
Retinopathy telescreening and risk assessment with digital imaging systems are used as an alternative to conventional dilated fundus examination in diabetic individuals. Digital imaging systems use a digital fundus camera to acquire a series of standard field color images and/or monochromatic images of the retina of each eye. Captured digital images may be transmitted via the Internet to a remote center for interpretation by trained readers, storage, and subsequent comparison.

MEDICAL CRITERIA
Not applicable

PRIOR AUTHORIZATION
Not applicable

POLICY STATEMENT
BlueCHiP for Medicare Products
Retinal telescreening with digital imaging and manual grading of images performed by a primary care provider (PCP), optometrist or ophthalmologist may be considered medically necessary as a screening technique for the detection of diabetic retinopathy or for monitoring and management of disease in individuals diagnosed with diabetic retinopathy.

Blue Cross & Blue Shield of Rhode Island (BCBSRI) must follow Centers for Medicare and Medicaid Services (CMS) guidelines, such as national coverage determinations or local coverage determinations for all BlueCHiP for Medicare policies. Therefore, BlueCHiP for Medicare policies may differ from Commercial products. In some instances, benefits for BlueCHiP for Medicare may be greater than what is allowed by the CMS.

Commercial Products
Retinal telescreening with digital imaging and manual grading of images performed by a primary care provider (PCP), optometrist or ophthalmologist may be considered medically necessary as a screening technique for the detection of diabetic retinopathy.

Retinal telescreening is considered not medically necessary for all other indications, including the monitoring and management of disease in individuals diagnosed with diabetic retinopathy as the evidence is insufficient to determine the effects of the technology on health outcomes.

BlueCHiP for Medicare and Commercial
Digital retinal imaging with automated image interpretation is considered not covered for BlueCHiP for Medicare products and not medically necessary for Commercial Products for the detection of diabetic retinopathy.

COVERAGE
Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable diagnostic testing and not medically necessary services benefits/coverage.
BACKGROUND
Diabetic retinopathy is the leading cause of blindness among adults aged 20 to 74 years in the United States. The major risk factors for developing diabetic retinopathy are duration of diabetes and severity of hyperglycemia. After 20 years of disease, almost all patients with type 1 and more than 60% of patients with type 2 diabetes will have some degree of retinopathy. Other factors that contribute to the risk of retinopathy include hypertension and elevated serum lipid levels.

Diabetic retinopathy progresses, at varying rates, from asymptomatic, mild nonproliferative abnormalities to proliferative diabetic retinopathy (PDR), with new blood vessel growth on the retina and posterior surface of the vitreous. The 2 most serious complications for vision are diabetic macular edema (DME) and PDR. At its earliest stage (nonproliferative retinopathy), the retina develops microaneurysms, intraretinal hemorrhages, and focal areas of retinal ischemia. With disruption of the blood-retinal barrier, macular retinal vessels become permeable, leading to exudation of serous fluid and lipids into the macula (macular edema). As the disease progresses, retinal blood vessels are blocked, triggering the growth of new and fragile blood vessels (proliferative retinopathy). The new blood vessels that occur in PDR may fibrose and contract, resulting in tractional retinal detachments with significant vision loss. Severe vision loss with proliferative retinopathy arises from vitreous hemorrhage. Moderate vision loss can also arise from macular edema (fluid accumulating in the center of the macula) during the proliferative or nonproliferative stages of the disease. Although proliferative disease is the main cause of blinding in diabetic retinopathy, macular edema is more frequent and is the leading cause of moderate vision loss in people with diabetes.

Screening
There is potential value in screening for diabetic retinopathy because diabetic retinopathy has few visual or ocular symptoms until vision loss develops. Because treatments are primarily aimed at preventing vision loss, and retinopathy can be asymptomatic, it is important to detect disease and begin treatment early in the process. Annual dilated, indirect ophthalmoscopy, coupled with biomicroscopy or 7-standard field stereoscopic 30° fundus photography, has been considered the screening technique of choice. Because these techniques require a dedicated visit to a competent eye care professional, typically an ophthalmologist, retinopathy screening is underutilized. This underuse has resulted in the exploration of remote retinal imaging, using film or digital photography, as an alternative to direct ophthalmic examination of the retina.

Treatment
With early detection, diabetic retinopathy can be treated with modalities that can decrease the risk of severe vision loss. Tight glycemic and blood pressure control is the first line of treatment to control diabetic retinopathy, followed by laser photocoagulation for patients whose retinopathy is approaching the high-risk stage. Although laser photocoagulation is effective at slowing the progression of retinopathy and reducing visual loss, it causes collateral damage to the retina and does not restore lost vision. Focal macular edema (characterized by leakage from discrete microaneurysms on fluorescein angiography) may be treated with focal laser photocoagulation, while diffuse macular edema (characterized by generalized macular edema on fluorescein angiography) may be treated with grid laser photocoagulation. Corticosteroids may reduce vascular permeability and inhibit vascular endothelial growth factor (VEGF) production, but are associated with serious adverse events including cataracts and glaucoma, with damage to the optic nerve. Corticosteroids also can worsen diabetes control. VEGF inhibitors (eg ranibizumab, bevacizumab, pegaptanib), which reduce permeability and block the pathway leading to new blood vessel formation (angiogenesis), are being evaluated for the treatment of DME and PDR.

Digital Photography and Transmission Systems for Retinal Imaging
A number of photographic methods have been evaluated that capture images of the retina to be interpreted by expert readers, who may or may not be located proximally to the patient. Retinal imaging can be performed using digital retinal photographs with (mydriatic) or without (nonmydriatic) dilating of the
pupil. One approach is mydriatic standard field 35-mm stereoscopic color fundus photography. Digital fundus photography has also been evaluated as an alternative to conventional film photography. Digital imaging has the advantage of easier acquisition, transmission, and storage. Digital images of the retina can also be acquired in a primary care setting and evaluated by trained readers in a remote location, in consultation with retinal specialists.

For individuals who have diabetes without known diabetic retinopathy who receive digital retinal imaging with optometrist or ophthalmologist image interpretation, the evidence includes retrospective studies comparing the accuracy of digital screening with standard methods, systematic reviews of these studies, and 1 randomized controlled trial (RCT). Relevant outcomes include test accuracy and validity, change in disease status, and functional outcomes. A number of studies have reported on the agreement between direct ophthalmoscopy and photography and between standard film and digital imaging in terms of the presence and stage of retinopathy. The studies have generally found high levels of agreement between retinal examination and imaging. There is limited direct evidence related to visual outcomes for patients evaluated with a strategy of retinal telescreening. However, given evidence from the large Early Treatment Diabetic Retinopathy Study (ETDRS) that early retinopathy treatment improves outcomes, coupled with studies showing high concordance between the screening methods used in ETDRS and 1 RCT demonstrating higher uptake of screening with a telescreening strategy, a strong chain of evidence can be made that telescreening is associated with improved health outcomes. Digital imaging systems have the additional advantages of short examination time and the ability to perform the test in the primary care physician setting. For individuals who cannot or would not be able to access an eye care professional at the recommended screening interv technology results in a meaningful improvement in the net health outcome.

For individuals who have diabetes without known diabetic retinopathy who receive digital retinal imaging with automated image interpretation, the evidence includes retrospective studies comparing the accuracy of automated scoring of digital images with standard methods. Relevant outcomes include test accuracy and validity, change in disease status, and functional outcomes. The available studies have tended to report high sensitivity with moderate specificity, although there is variability across studies. In addition, available studies have reported on different automated interpretation systems. These scoring systems have potential to improve screening in the primary care setting. However, given the variability in test characteristics across different systems, there is uncertainty about the accuracy of automated scoring systems in practice. The evidence is insufficient to determine the effects of the technology on health outcomes.

**Fundus Photography**

Provision of fundus photography, by providers other than ophthalmologists or optometrists, as a screening test to facilitate referral to a specialist is contrary to requirements for testing as codified in 42CFR 410.32. Furthermore, the ordering/performance of fundus photography by eye specialists prior to a face-to-face encounter is similarly not covered or reimbursable.

**Regulatory Status**

Several digital camera and transmission systems (see Table 1 for examples) have been cleared for marketing by the U.S. Food and Drug Administration (FDA) through the 510(k) process and are currently available (product codes: HKI and NFJ). Several Brand names are IRIS Intelligent Retinal Imaging System™, DigiScope®, The Fundus AutoImager, ImageNet™ Digital Imaging System, and Zeiss FF450 Fundus Camera and the VISUPAC Digital Imaging System.

**CODING**

**BlueCHiP for Medicare Products**

The following codes are covered and separately reimbursed when filed by primary care provider (PCP), optometrist or ophthalmologist

92227 Remote imaging for detection of retinal disease (eg, retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral
92228 Remote imaging for monitoring and management of active retinal disease (eg, diabetic retinopathy) with physician review, interpretation and report, unilateral or bilateral

Commercial Products
The following codes are covered and separately reimbursed when filed by primary care providers (PCP), optometrists or ophthalmologists
92227 Remote imaging for detection of retinal disease (e.g., retinopathy in a patient with diabetes) with analysis and report under physician supervision, unilateral or bilateral

The following code is not medically necessary
92228 Remote imaging for monitoring and management of active retinal disease (e.g., diabetic retinopathy) with physician review, interpretation and report, unilateral or bilateral

BlueCHiP for Medicare and Commercial Products
To ensure correct claims processing PCP’s MUST include one of the Category II codes below. Claims filed without one of these additional CPT code will not be reimbursed:

For optometrists or ophthalmologists, use of CAT II codes is optional and will not impact claims processing.

2022F Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; with evidence of retinopathy (DM)
2023F Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)

It is incorrect coding to file 92227 and 92228 codes with modifier TC or 26 as the codes include the technical and interpretation and report components.

It is incorrect coding to file for these services using the following CPT code:
92250 Fundus Photography with physician review, interpretation and report, unilateral or bilateral

BlueCHiP for Medicare and Commercial Products
The following code is not covered/Medically necessary.
92229 Dilated retinal eye exam point of care automated analysis and report, unilateral or bilateral (new code effective 1/1/2021)

RELATED POLICIES
Not applicable

PUBLISHED
Provider Update December 2020
Provider Update, August 2019
Provider Update, July 2018
Provider Update, July 2017

REFERENCES:

CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member’s subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.